NASDAQ: GALT - Galectin Therapeutics Inc.

Rentabilität für sechs Monate: -49.56%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Galectin Therapeutics Inc.


Über das Unternehmen Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

weitere details
The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

IPO date 2002-09-09
ISIN US3632252025
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://galectintherapeutics.com
Цена ао 2.37
Preisänderung pro Tag: +32.17% (0.8701)
Preisänderung pro Woche: +10.58% (1.04)
Preisänderung pro Monat: -59.44% (2.835)
Preisänderung über 3 Monate: -57.56% (2.71)
Preisänderung über sechs Monate: -49.56% (2.28)
Preisänderung pro Jahr: -30.72% (1.66)
Preisänderung über 3 Jahre: -50.43% (2.32)
Preisänderung über 5 Jahre: -62.05% (3.03)
Preisänderung über 10 Jahre: 0% (1.15)
Preisänderung seit Jahresbeginn: -60.21% (2.89)

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV -1.77 0
P/E 0 0
EV/EBITDA -4.01 0
Gesamt: 2.5

Effizienz

Name Bedeutung Grad
ROA, % -145.62 0
ROE, % 68.17 10
Gesamt: 3.33

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -1.89 10
Gesamt: 9

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % -98.47 0
Rentabilität EPS, % 166.44 10
Gesamt: 6

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
iShares Micro-Cap ETF 0.01442 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00247 38.04 0.6026
ProShares UltraPro Russell2000 0.00122 89.82 1.47873
ProShares Hedge Replication ETF 0.00034 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
031.851.2



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Joel Lewis President, CEO & Director 907.72k 1970 (55 Jahre)
Mr. Jack W. Callicutt CPA CFO, Treasurer & Corporate Secretary 521.47k 1967 (58 Jahre)
Robert Tritt General Counsel N/A
Mr. Jeff Katstra Head of CMC & Pharmaceutical Development N/A
Ms. Beth Knowles Executive Assistant & Officer Manager N/A
Mr. Khurram Jamil M.D. Chief Medical Officer

Adresse: United States, Norcross. GA, 4960 Peachtree Industrial Boulevard - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://galectintherapeutics.com